Abstract: SA-PO0649
Serum Gd-IgA1 and Gd-IgA1/C3 Ratio as Predictors of Pathological Features and Treatment Response to Nefecon in Patients with IgAN
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Yang, Min, The Third Affiliated Hospital of Soochow University, Jiangsu, China
- Zhang, Chaoqun, The Third Affiliated Hospital of Soochow University, Jiangsu, China
- Zou, Yun, The Third Affiliated Hospital of Soochow University, Jiangsu, China
Background
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Nefecon effectively reduces serum Gd-IgA1 and proteinuria, but the predictive value of Gd-IgA1 and Gd-IgA1/C3 ratio for pathological lesions and treatment response to Nefecon remains unclear.
Methods
We enrolled 15 biopsy-confirmed IgAN patients treated with Nefecon. Clinical parameters, baseline serum Gd-IgA1, Gd-IgA1/C3 ratio, and Oxford MEST-C pathological features were collected. Patients were divided into high and low groups by the median values of baseline Gd- IgA1 and Gd-IgA1/C3 ratio(both high groups n=7, low groups n=8). Very Early Response (VER) was defined as a ≥30% reduction in 24 hour urinary total protein (UTP) from baseline at 3 months.
Results
Mean eGFR was 84.91±26.06 ml/min/1.73m^2, median UTP was 1.85(1.18,2.96)g/day, baseline Gd IgA1 42.34(23.76,102.40)ng/mL and Gd-IgA1/C3 ratio 32.84(17.06,70.61)(Figure 1). Patients in the high baseline Gd-IgA1 and Gd-IgA1/C3 ratio groups had a significantly higher prevalence of S1(all P<0.05)(Figure 2), and exhibited a significantly higher VER rate (both P<0.05)(Figure 2). UTP decreased by 40.97% from baseline at 3 months.
Conclusion
Higher baseline serum Gd-IgA1 levels and Gd-IgA1/C3 ratio were closely associated with S1 and a better VER rate following early Nefecon treatment. These biomarkers may facilitate risk stratification and personalized therapeutic strategies in IgAN.